Cancer Cure Books » Pivotal http://cancercurebooks.com/blog Thu, 09 Sep 2010 23:38:40 +0000 http://wordpress.org/?v=2.8.6 en hourly 1 Guided Therapeutics’ LightTouch Cervical Scan Detected Disease Up To Two Years Earlier Than Pap, HPV And Biopsy In FDA Pivotal Clinical Trial http://cancercurebooks.com/blog/guided-therapeutics-lighttouch-cervical-scan-detected-disease-up-to-two-years-earlier-than-pap-hpv-and-biopsy-in-fda-pivotal-clinical-trial http://cancercurebooks.com/blog/guided-therapeutics-lighttouch-cervical-scan-detected-disease-up-to-two-years-earlier-than-pap-hpv-and-biopsy-in-fda-pivotal-clinical-trial#comments Sun, 04 Apr 2010 03:30:54 +0000 Doctor http://cancercurebooks.com/blog/guided-therapeutics-lighttouch-cervical-scan-detected-disease-up-to-two-years-earlier-than-pap-hpv-and-biopsy-in-fda-pivotal-clinical-trial

Some Women with Significant Cervical Disease Could Have Been Diagnosed Up to two years earlier using the Guided Therapeutics, Inc. (GT) LightTouch Cervical Scanner, according to results of a U.S. Food and Drug Administration (FDA) pivotal clinical trial being presented at the American Society for Colposcopy and Cervical Pathology biennial meeting. Source: General Cancer News Articles Provided by Cancer Compass

Share/Bookmark]]> http://cancercurebooks.com/blog/guided-therapeutics-lighttouch-cervical-scan-detected-disease-up-to-two-years-earlier-than-pap-hpv-and-biopsy-in-fda-pivotal-clinical-trial/feed 0 Denosumab Demonstrated Superiority Over Zometa In Pivotal Phase 3 Head-To-Head Trial In Prostate Cancer Patients With Bone Metastases http://cancercurebooks.com/blog/denosumab-demonstrated-superiority-over-zometa-in-pivotal-phase-3-head-to-head-trial-in-prostate-cancer-patients-with-bone-metastases http://cancercurebooks.com/blog/denosumab-demonstrated-superiority-over-zometa-in-pivotal-phase-3-head-to-head-trial-in-prostate-cancer-patients-with-bone-metastases#comments Sun, 21 Feb 2010 09:40:06 +0000 Doctor http://cancercurebooks.com/blog/denosumab-demonstrated-superiority-over-zometa-in-pivotal-phase-3-head-to-head-trial-in-prostate-cancer-patients-with-bone-metastases

Amgen announced that a pivotal, Phase 3, head-to- head trial evaluating denosumab versus Zometa (zoledronic acid) in the treatment of bone metastases in 1,901 men with advanced prostate cancer met its primary and secondary endpoints. Source: General Cancer News Articles Provided by Cancer Compass

Share/Bookmark]]> http://cancercurebooks.com/blog/denosumab-demonstrated-superiority-over-zometa-in-pivotal-phase-3-head-to-head-trial-in-prostate-cancer-patients-with-bone-metastases/feed 0 Medifocus, Inc. Announces Food And Drug Administration FDA Update For Its Pivotal Phase III Clinical Trial For Treatment Of Breast Cancer: Files Response To Two Remaining Questions http://cancercurebooks.com/blog/medifocus-inc-announces-food-and-drug-administration-fda-update-for-its-pivotal-phase-iii-clinical-trial-for-treatment-of-breast-cancer-files-response-to-two-remaining-questions http://cancercurebooks.com/blog/medifocus-inc-announces-food-and-drug-administration-fda-update-for-its-pivotal-phase-iii-clinical-trial-for-treatment-of-breast-cancer-files-response-to-two-remaining-questions#comments Tue, 09 Feb 2010 04:58:54 +0000 Doctor http://cancercurebooks.com/blog/medifocus-inc-announces-food-and-drug-administration-fda-update-for-its-pivotal-phase-iii-clinical-trial-for-treatment-of-breast-cancer-files-response-to-two-remaining-questions

Medifocus, Inc. is pleased to announce that it has filed on January 22, 2010, its response to two (2) remaining questions with the FDA in the United States of America (USA) to obtain clearance to initiate a pivotal phase III clinical trial using the Company’s Microfocus APA 1000 System for the treatment of breast cancer in the USA and worldwide. Source: General Cancer News Articles Provided by Cancer Compass

Share/Bookmark]]> http://cancercurebooks.com/blog/medifocus-inc-announces-food-and-drug-administration-fda-update-for-its-pivotal-phase-iii-clinical-trial-for-treatment-of-breast-cancer-files-response-to-two-remaining-questions/feed 0